Airway diseases

State of the art session
Chairs: O. Usmani (London, United Kingdom), A. Yorgancioglu (Konak, Turkey)
Aims: To evaluate the use of short-acting ß-2 agonist (SABA) monotherapy versus maintenance and reliever therapy (MART) and triple therapy for asthma; to describe new treatments for chronic cough; to determine the optimal endoscopic procedure for different patients with chronic obstructive pulmonary disease (COPD) and asthma; to discuss the role of artificial intelligence in asthma and COPD treatment.

How to treat asthma in 2021? Goodbye SABA, hello MART and welcome triple therapy A. Papi (Ferrara, Italy)
New treatments for chronic cough J. Smith (Manchester (Greater Manchester), United Kingdom)
Which endoscopic procedure to use and in what patient? Valves, coils, foam and heat in COPD and asthma L. Pyng (Singapore, Singapore)
Will artificial intelligence really transform clinical practice? Applications in asthma and COPD K. Kostikas (Ioannina, Greece)
Discussion and Q&A